Published in Gastroenterology on June 01, 2006
Metformin and the fate of fat. Gastroenterology (2006) 2.18
Mitochondrial dysfunction and oxidative stress in the pathogenesis of alcohol- and obesity-induced fatty liver diseases. Free Radic Biol Med (2008) 2.14
Alcohol and lipid metabolism. Am J Physiol Endocrinol Metab (2008) 1.79
Molecular mechanisms of alcoholic fatty liver. Alcohol Clin Exp Res (2008) 1.59
AMP-activated protein kinase pathway: a potential therapeutic target in cardiometabolic disease. Clin Sci (Lond) (2009) 1.43
Fibrin accumulation plays a critical role in the sensitization to lipopolysaccharide-induced liver injury caused by ethanol in mice. Hepatology (2009) 1.23
Mechanisms and cell signaling in alcoholic liver disease. Biol Chem (2010) 1.19
The emerging role of autophagy in alcoholic liver disease. Exp Biol Med (Maywood) (2011) 1.13
Metformin prevents and reverses inflammation in a non-diabetic mouse model of nonalcoholic steatohepatitis. PLoS One (2012) 1.13
Binge ethanol and liver: new molecular developments. Alcohol Clin Exp Res (2013) 1.13
Inflammatory stress and idiosyncratic hepatotoxicity: hints from animal models. Pharmacol Rev (2009) 1.12
"Second hit" models of alcoholic liver disease. Semin Liver Dis (2009) 1.12
Plasminogen activator inhibitor-1 limits liver injury and facilitates regeneration after acetaminophen overdose. Toxicol Sci (2008) 1.11
Similarities and differences in the pathogenesis of alcoholic and nonalcoholic steatohepatitis. Semin Liver Dis (2009) 1.08
PAI-1 plays a protective role in CCl4-induced hepatic fibrosis in mice: role of hepatocyte division. Am J Physiol Gastrointest Liver Physiol (2010) 1.06
CYP2E1 potentiates binge alcohol-induced gut leakiness, steatohepatitis, and apoptosis. Free Radic Biol Med (2013) 1.06
Metformin inhibits the growth of human pancreatic cancer xenografts. Pancreas (2013) 1.05
New role of resistin in lipopolysaccharide-induced liver damage in mice. J Pharmacol Exp Ther (2008) 1.02
Toxicant-associated steatohepatitis. Toxicol Pathol (2012) 1.01
Contribution of the sympathetic hormone epinephrine to the sensitizing effect of ethanol on LPS-induced liver damage in mice. Am J Physiol Gastrointest Liver Physiol (2008) 1.01
New role of plasminogen activator inhibitor-1 in alcohol-induced liver injury. J Gastroenterol Hepatol (2008) 1.00
Pathogenesis of alcoholic liver disease: the role of nuclear receptors. Exp Biol Med (Maywood) (2010) 1.00
Advances in alcoholic liver disease. Curr Gastroenterol Rep (2011) 0.98
Subhepatotoxic exposure to arsenic enhances lipopolysaccharide-induced liver injury in mice. Toxicol Appl Pharmacol (2007) 0.98
Deficiency in AMPK attenuates ethanol-induced cardiac contractile dysfunction through inhibition of autophagosome formation. Cardiovasc Res (2012) 0.97
Alcoholic liver disease and the potential role of plasminogen activator inhibitor-1 and fibrin metabolism. Exp Biol Med (Maywood) (2012) 0.96
Chronic subhepatotoxic exposure to arsenic enhances hepatic injury caused by high fat diet in mice. Toxicol Appl Pharmacol (2011) 0.95
Histological course of nonalcoholic fatty liver disease in Japanese patients: tight glycemic control, rather than weight reduction, ameliorates liver fibrosis. Diabetes Care (2009) 0.94
Olanzapine activates hepatic mammalian target of rapamycin: new mechanistic insight into metabolic dysregulation with atypical antipsychotic drugs. J Pharmacol Exp Ther (2013) 0.91
PKCepsilon plays a causal role in acute ethanol-induced steatosis. Arch Biochem Biophys (2008) 0.91
Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care (2014) 0.91
Acute alcohol-induced liver injury. Front Physiol (2012) 0.90
Involvement of AMPK in alcohol dehydrogenase accentuated myocardial dysfunction following acute ethanol challenge in mice. PLoS One (2010) 0.89
Prenatal androgenization of female mice programs an increase in firing activity of gonadotropin-releasing hormone (GnRH) neurons that is reversed by metformin treatment in adulthood. Endocrinology (2010) 0.88
The role of intestinal bacteria overgrowth in obesity-related nonalcoholic fatty liver disease. Nutrients (2014) 0.88
Ethanol and liver: recent insights into the mechanisms of ethanol-induced fatty liver. World J Gastroenterol (2014) 0.87
The antifibrinolytic drug tranexamic acid reduces liver injury and fibrosis in a mouse model of chronic bile duct injury. J Pharmacol Exp Ther (2014) 0.87
Metformin Inhibits Isoproterenol-induced Cardiac Hypertrophy in Mice. Korean J Physiol Pharmacol (2010) 0.86
Antihyperglycemic mechanism of metformin occurs via the AMPK/LXRα/POMC pathway. Sci Rep (2015) 0.86
Metformin attenuates pressure overload-induced cardiac hypertrophy via AMPK activation. Acta Pharmacol Sin (2011) 0.85
Acute ethanol preexposure promotes liver regeneration after partial hepatectomy in mice by activating ALDH2. Am J Physiol Gastrointest Liver Physiol (2013) 0.85
Increased dietary fat contributes to dysregulation of the LKB1/AMPK pathway and increased damage in a mouse model of early-stage ethanol-mediated steatosis. J Nutr Biochem (2013) 0.84
Proteasome inhibitor treatment reduced fatty acid, triacylglycerol and cholesterol synthesis. Exp Mol Pathol (2012) 0.83
Gut microbiome in health and disease: Linking the microbiome-gut-brain axis and environmental factors in the pathogenesis of systemic and neurodegenerative diseases. Pharmacol Ther (2015) 0.82
Risk factors for alcohol-related liver injury in the island population of China: a population-based case-control study. World J Gastroenterol (2008) 0.81
Optimal management for alcoholic liver disease: Conventional medications, natural therapy or combination? World J Gastroenterol (2016) 0.80
Transient receptor potential vanilloid 1 gene deficiency ameliorates hepatic injury in a mouse model of chronic binge alcohol-induced alcoholic liver disease. Am J Pathol (2014) 0.80
Transitional Remodeling of the Hepatic Extracellular Matrix in Alcohol-Induced Liver Injury. Biomed Res Int (2016) 0.78
Liver-specific Gene Inactivation of the Transcription Factor ATF4 Alleviates Alcoholic Liver Steatosis in Mice. J Biol Chem (2016) 0.77
Role of Fibrin(ogen) in Progression of Liver Disease: Guilt by Association? Semin Thromb Hemost (2016) 0.76
Metabolic derivatives of alcohol and the molecular culprits of fibro-hepatocarcinogenesis: Allies or enemies? World J Gastroenterol (2016) 0.76
PKCε contributes to chronic ethanol-induced steatosis in mice but not inflammation and necrosis. Alcohol Clin Exp Res (2014) 0.75
Insulin resistance in clinical and experimental alcoholic liver disease. Ann N Y Acad Sci (2015) 0.75
Alcohol Modulation of the Postburn Hepatic Response. J Burn Care Res (2015) 0.75
Effects of S-Adenosylmethionine and Its Combinations With Taurine and/or Betaine on Glutathione Homeostasis in Ethanol-induced Acute Hepatotoxicity. J Cancer Prev (2016) 0.75
Herbal SGR Formula Prevents Acute Ethanol-Induced Liver Steatosis via Inhibition of Lipogenesis and Enhancement Fatty Acid Oxidation in Mice. Evid Based Complement Alternat Med (2015) 0.75
Hepatorenal repercussions of alcoholic exposure in a rat model: a dose-dependent study of metformin intervention. Iran Biomed J (2012) 0.75
The hepatic "matrisome" responds dynamically to injury: Characterization of transitional changes to the extracellular matrix in mice. Hepatology (2016) 0.75
Fibrin-mediated integrin signaling plays a critical role in hepatic regeneration after partial hepatectomy in mice. Ann Hepatol (2016) 0.75
Effect of acute beer ingestion on the liver: studies in female mice. Eur J Nutr (2014) 0.75
Plasminogen Activator Inhibitor-1 is Critical in Alcohol-enhanced Acute Lung Injury in Mice. Am J Respir Cell Mol Biol (2017) 0.75
Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest (2001) 23.21
Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science (1991) 8.68
Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology (2001) 8.09
Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med (2000) 5.13
Inhibition of cytokine production by cyclosporin A and transforming growth factor beta. J Exp Med (1987) 4.35
Metformin in non-alcoholic steatohepatitis. Lancet (2001) 3.63
Essential role of tumor necrosis factor alpha in alcohol-induced liver injury in mice. Gastroenterology (1999) 3.24
NADPH oxidase-derived free radicals are key oxidants in alcohol-induced liver disease. J Clin Invest (2000) 2.67
Characterization of the activation of latent TGF-beta by co-cultures of endothelial cells and pericytes or smooth muscle cells: a self-regulating system. J Cell Biol (1990) 2.65
Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. Lancet (1995) 2.64
Antibiotics prevent liver injury in rats following long-term exposure to ethanol. Gastroenterology (1995) 2.58
The role of AMP-activated protein kinase in the action of ethanol in the liver. Gastroenterology (2004) 2.50
Inactivation of Kupffer cells prevents early alcohol-induced liver injury. Hepatology (1994) 2.37
Oxidants and antioxidants in alcohol-induced liver disease. Gastroenterology (2003) 2.37
Alcohollike liver disease in nonalcoholics. A clinical and histologic comparison with alcohol-induced liver injury. Gastroenterology (1988) 2.20
Beef fat prevents alcoholic liver disease in the rat. Alcohol Clin Exp Res (1989) 2.18
Biological activation of pro-HGF (hepatocyte growth factor) by urokinase is controlled by a stoichiometric reaction. J Biol Chem (1995) 2.06
Epidemiology of alcoholic liver disease. Semin Liver Dis (1988) 1.96
Hepatic steatosis: innocent bystander or guilty party? Hepatology (1998) 1.94
Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes (2004) 1.85
Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta. J Clin Invest (1991) 1.85
Recent advances in alcoholic liver disease II. Minireview: molecular mechanisms of alcoholic fatty liver. Am J Physiol Gastrointest Liver Physiol (2004) 1.78
The pathogenesis of nonalcoholic steatohepatitis and other fatty liver diseases: a four-step model including the role of lipid release and hepatic venular obstruction in the progression to cirrhosis. Semin Liver Dis (2004) 1.62
Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther (2004) 1.61
Inducible nitric oxide synthase is required in alcohol-induced liver injury: studies with knockout mice. Gastroenterology (2003) 1.59
Plasminogen activator inhibitors--a review. Enzyme (1988) 1.53
Chronic enteral ethanol treatment causes hypoxia in rat liver tissue in vivo. Hepatology (1997) 1.45
The role of gut-derived bacterial toxins and free radicals in alcohol-induced liver injury. J Gastroenterol Hepatol (1998) 1.40
Pioglitazone prevents alcohol-induced fatty liver in rats through up-regulation of c-Met. Gastroenterology (2004) 1.35
Critical role of plasminogen activator inhibitor-1 in cholestatic liver injury and fibrosis. J Pharmacol Exp Ther (2005) 1.33
Histologic spectrum of alcoholic liver disease. Semin Liver Dis (1986) 1.33
The effect of defibrination on macrophage participation in rabbit nephrotoxic nephritis: studies using glomerular culture and electronmicroscopy. Clin Exp Immunol (1979) 1.28
Plasminogen activator inhibitor-1 is a significant determinant of renal injury in experimental crescentic glomerulonephritis. J Am Soc Nephrol (2003) 1.22
Kupffer cell-derived prostaglandin E(2) is involved in alcohol-induced fat accumulation in rat liver. Am J Physiol Gastrointest Liver Physiol (2000) 1.20
Mechanism of the alcohol cyclic pattern: role of the hypothalamic-pituitary-thyroid axis. Am J Physiol Gastrointest Liver Physiol (2000) 1.20
Fibrin regulates neutrophil migration in response to interleukin 8, leukotriene B4, tumor necrosis factor, and formyl-methionyl-leucyl-phenylalanine. J Exp Med (1995) 1.19
Plasma PAI-1 levels are more strongly related to liver steatosis than to adipose tissue accumulation. Arterioscler Thromb Vasc Biol (2003) 1.16
Metformin prevents endotoxin-induced liver injury after partial hepatectomy. J Pharmacol Exp Ther (2005) 1.12
Plasminogen activator inhibitor-1 supports IL-8-mediated neutrophil transendothelial migration by inhibition of the constitutive shedding of endothelial IL-8/heparan sulfate/syndecan-1 complexes. J Immunol (2003) 1.10
Effects of ethanol ingestion and dietary fat levels on mitochondrial lipids in male and female rats. Lipids (1978) 1.09
Fish oil, alcohol, and liver pathology: role of cytochrome P450 2E1. Proc Soc Exp Biol Med (1994) 1.08
Decreased microsomal triglyceride transfer protein activity contributes to initiation of alcoholic liver steatosis in rats. J Hepatol (2002) 1.04
Effect of chronic ethanol feeding on the hepatic secretion of very-low-density lipoproteins. Biochim Biophys Acta (1988) 1.04
The application of lipid-soluble stains in plastic-embedded sections. Histochemistry (1986) 1.02
Cocoa extract protects against early alcohol-induced liver injury in the rat. Arch Biochem Biophys (2002) 1.02
Fat and the liver--a molecular overview. Semin Gastrointest Dis (2002) 0.99
Induction of plasminogen activator inhibitor 1 gene expression in murine liver by lipopolysaccharide. Cellular localization and role of endogenous tumor necrosis factor-alpha. Am J Pathol (1997) 0.99
Hepatocyte growth factor leads to recovery from alcohol-induced fatty liver in rats. J Clin Invest (1999) 0.95
Pathological spectrum of alcoholic liver disease. Alcohol Alcohol Suppl (1994) 0.93
Zonal heterogeneity of the effects of chronic ethanol feeding on hepatic fatty acid metabolism. Hepatology (1990) 0.92
Nimodipine, a dihydropyridine-type calcium channel blocker, prevents alcoholic hepatitis caused by chronic intragastric ethanol exposure in the rat. Hepatology (1996) 0.87
Metformin-induced lactic acidosis: potentiation by ethanol. Res Commun Chem Pathol Pharmacol (1981) 0.87
Plasminogen activator inhibitor-1 synthesis in the human hepatoma cell line Hep G2. Metformin inhibits the stimulating effect of insulin. J Clin Invest (1993) 0.86
Insulin resistance in patients with steatohepatitis. Hepatogastroenterology (2003) 0.85
Metformin causes a reduction in basal and post-venous occlusion plasminogen activator inhibitor-1 in type 2 diabetic patients. Diabet Med (1991) 0.85
Interleukin-1 induction of type-1 plasminogen activator inhibitor (PAI-1) gene expression in the mouse hepatocyte line, AML 12. J Cell Physiol (1996) 0.85
Hepatocyte growth factor stimulates synthesis of lipids and secretion of lipoproteins in rat hepatocytes. Hepatology (1998) 0.84
Metabolic effects of glucocorticoid and ethanol administration in phenformin- and metformin-treated obese diabetics. Acta Med Scand (1979) 0.81
Effects of glibenclamide, metformin and insulin on the incidence and latency of death by oubain-induced arrhythmias in mice. Pharmacol Res (2002) 0.80
Comparing the Gleason prostate biopsy and Gleason prostatectomy grading system: the Lahey Clinic Medical Center experience and an international meta-analysis. Eur Urol (2008) 2.77
Hyperglycemia-induced apoptosis in mouse myocardium: mitochondrial cytochrome C-mediated caspase-3 activation pathway. Diabetes (2002) 2.44
Inducible nitric oxide synthase is required in alcohol-induced liver injury: studies with knockout mice. Gastroenterology (2003) 1.59
Monocyte tissue factor-dependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin. J Clin Invest (2012) 1.51
Differential roles of unsaturated and saturated fatty acids on autophagy and apoptosis in hepatocytes. J Pharmacol Exp Ther (2011) 1.49
Adverse hepatic drug reactions: inflammatory episodes as consequence and contributor. Chem Biol Interact (2004) 1.49
Lipopolysaccharide and trovafloxacin coexposure in mice causes idiosyncrasy-like liver injury dependent on tumor necrosis factor-alpha. Toxicol Sci (2007) 1.45
A critical involvement of oxidative stress in acute alcohol-induced hepatic TNF-alpha production. Am J Pathol (2003) 1.41
Farnesoid X receptor deficiency induces nonalcoholic steatohepatitis in low-density lipoprotein receptor-knockout mice fed a high-fat diet. J Pharmacol Exp Ther (2008) 1.36
Role of lipopolysaccharide-binding protein in early alcohol-induced liver injury in mice. J Immunol (2002) 1.34
Critical role of plasminogen activator inhibitor-1 in cholestatic liver injury and fibrosis. J Pharmacol Exp Ther (2005) 1.33
Role of the coagulation system in acetaminophen-induced hepatotoxicity in mice. Hepatology (2007) 1.23
Fibrin accumulation plays a critical role in the sensitization to lipopolysaccharide-induced liver injury caused by ethanol in mice. Hepatology (2009) 1.23
The coagulation system contributes to alphaVbeta6 integrin expression and liver fibrosis induced by cholestasis. Am J Pathol (2010) 1.21
Ranitidine treatment during a modest inflammatory response precipitates idiosyncrasy-like liver injury in rats. J Pharmacol Exp Ther (2003) 1.17
COX-2 suppresses tissue factor expression via endocannabinoid-directed PPARdelta activation. J Exp Med (2007) 1.16
Microarray analysis of lipopolysaccharide potentiation of trovafloxacin-induced liver injury in rats suggests a role for proinflammatory chemokines and neutrophils. J Pharmacol Exp Ther (2005) 1.15
Crystal structure of the antioxidant enzyme glutathione reductase inactivated by peroxynitrite. J Biol Chem (2001) 1.14
Role of the renin-angiotensin system in hepatic ischemia reperfusion injury in rats. Hepatology (2004) 1.13
Role of neutrophils in the synergistic liver injury from monocrotaline and bacterial lipopolysaccharide exposure. Toxicol Sci (2003) 1.13
Binge ethanol and liver: new molecular developments. Alcohol Clin Exp Res (2013) 1.13
Inflammatory stress and idiosyncratic hepatotoxicity: hints from animal models. Pharmacol Rev (2009) 1.12
Metformin prevents endotoxin-induced liver injury after partial hepatectomy. J Pharmacol Exp Ther (2005) 1.12
TNFalpha is required for cholestasis-induced liver fibrosis in the mouse. Biochem Biophys Res Commun (2008) 1.11
Treatment of alcoholic liver disease. Dig Dis (2005) 1.10
Incorporating new technologies into toxicity testing and risk assessment: moving from 21st century vision to a data-driven framework. Toxicol Sci (2013) 1.10
The role of tumor necrosis factor alpha in lipopolysaccharide/ranitidine-induced inflammatory liver injury. Toxicol Sci (2007) 1.09
PAR-1 contributes to the innate immune response during viral infection. J Clin Invest (2013) 1.09
Contribution of host-derived tissue factor to tumor neovascularization. Arterioscler Thromb Vasc Biol (2008) 1.08
Insulin activation of the phosphatidylinositol 3-kinase/protein kinase B (Akt) pathway reduces lipopolysaccharide-induced inflammation in mice. J Pharmacol Exp Ther (2008) 1.07
Modest inflammation enhances diclofenac hepatotoxicity in rats: role of neutrophils and bacterial translocation. J Pharmacol Exp Ther (2006) 1.07
Coagulation-mediated hypoxia and neutrophil-dependent hepatic injury in rats given lipopolysaccharide and ranitidine. J Pharmacol Exp Ther (2005) 1.06
PAI-1 plays a protective role in CCl4-induced hepatic fibrosis in mice: role of hepatocyte division. Am J Physiol Gastrointest Liver Physiol (2010) 1.06
Cardiac metallothionein synthesis in streptozotocin-induced diabetic mice, and its protection against diabetes-induced cardiac injury. Am J Pathol (2005) 1.06
Idiosyncratic drug-induced liver injury and the role of inflammatory stress with an emphasis on an animal model of trovafloxacin hepatotoxicity. Toxicol Sci (2010) 1.06
Endothelial cell injury and fibrin deposition in rat liver after monocrotaline exposure. Toxicol Sci (2002) 1.06
Role of hepatic fibrin in idiosyncrasy-like liver injury from lipopolysaccharide-ranitidine coexposure in rats. Hepatology (2004) 1.06
MetPP: a computational platform for comprehensive two-dimensional gas chromatography time-of-flight mass spectrometry-based metabolomics. Bioinformatics (2013) 1.06
Inflammation and drug idiosyncrasy--is there a connection? J Pharmacol Exp Ther (2003) 1.05
Exacerbation of diabetes-induced testicular apoptosis by zinc deficiency is most likely associated with oxidative stress, p38 MAPK activation, and p53 activation in mice. Toxicol Lett (2010) 1.05
Early growth response-1 contributes to galactosamine/lipopolysaccharide-induced acute liver injury in mice. Am J Physiol Gastrointest Liver Physiol (2007) 1.05
Hypoxia, drug therapy and toxicity. Pharmacol Ther (2006) 1.04
Application of transcriptional benchmark dose values in quantitative cancer and noncancer risk assessment. Toxicol Sci (2010) 1.03
Monocyte chemoattractant protein-1 deficiency does not affect steatosis or inflammation in livers of mice fed a methionine-choline-deficient diet. Lab Invest (2010) 1.02
New role of resistin in lipopolysaccharide-induced liver damage in mice. J Pharmacol Exp Ther (2008) 1.02
Cocoa extract protects against early alcohol-induced liver injury in the rat. Arch Biochem Biophys (2002) 1.02
Current experimental perspectives on the clinical progression of alcoholic liver disease. Alcohol Clin Exp Res (2009) 1.02
Toxicant-associated steatohepatitis. Toxicol Pathol (2012) 1.01
Prenatal arsenic exposure alters gene expression in the adult liver to a proinflammatory state contributing to accelerated atherosclerosis. PLoS One (2012) 1.01
Underlying endotoxemia augments toxic responses to chlorpromazine: is there a relationship to drug idiosyncrasy? J Pharmacol Exp Ther (2002) 1.01
Contribution of the sympathetic hormone epinephrine to the sensitizing effect of ethanol on LPS-induced liver damage in mice. Am J Physiol Gastrointest Liver Physiol (2008) 1.01
Bacterial- and viral-induced inflammation increases sensitivity to acetaminophen hepatotoxicity. J Toxicol Environ Health A (2010) 1.01
Tumor necrosis factor alpha is a proximal mediator of synergistic hepatotoxicity from trovafloxacin/lipopolysaccharide coexposure. J Pharmacol Exp Ther (2008) 0.99
Rapamycin enhances LPS induction of tissue factor and tumor necrosis factor-alpha expression in macrophages by reducing IL-10 expression. Mol Immunol (2009) 0.99
Small heterodimer partner overexpression partially protects against liver tumor development in farnesoid X receptor knockout mice. Toxicol Appl Pharmacol (2013) 0.99
Temporal concordance between apical and transcriptional points of departure for chemical risk assessment. Toxicol Sci (2013) 0.98
Advances in alcoholic liver disease. Curr Gastroenterol Rep (2011) 0.98
Subhepatotoxic exposure to arsenic enhances lipopolysaccharide-induced liver injury in mice. Toxicol Appl Pharmacol (2007) 0.98
Dependence of liver injury after hemorrhage/resuscitation in mice on NADPH oxidase-derived superoxide. Shock (2003) 0.98
Application of high-throughput Fourier-transform infrared spectroscopy in toxicology studies: contribution to a study on the development of an animal model for idiosyncratic toxicity. Toxicol Lett (2004) 0.97
Hepatotoxic interaction of sulindac with lipopolysaccharide: role of the hemostatic system. Toxicol Sci (2008) 0.96
Protease-activated receptor 1 and hematopoietic cell tissue factor are required for hepatic steatosis in mice fed a Western diet. Am J Pathol (2011) 0.96
Alcoholic liver disease and the potential role of plasminogen activator inhibitor-1 and fibrin metabolism. Exp Biol Med (Maywood) (2012) 0.96
Metallothionein-independent zinc protection from alcoholic liver injury. Am J Pathol (2002) 0.96
Chronic subhepatotoxic exposure to arsenic enhances hepatic injury caused by high fat diet in mice. Toxicol Appl Pharmacol (2011) 0.95
Modeling inflammation-drug interactions in vitro: a rat Kupffer cell-hepatocyte coculture system. Toxicol In Vitro (2006) 0.94
Ethanol and dietary unsaturated fat (corn oil/linoleic acid enriched) cause intestinal inflammation and impaired intestinal barrier defense in mice chronically fed alcohol. Alcohol (2013) 0.94
Protective and damaging effects of platelets in acute cholestatic liver injury revealed by depletion and inhibition strategies. Toxicol Sci (2010) 0.94
Coexposure of mice to trovafloxacin and lipopolysaccharide, a model of idiosyncratic hepatotoxicity, results in a unique gene expression profile and interferon gamma-dependent liver injury. Toxicol Sci (2008) 0.94
Modes of cell death in rat liver after monocrotaline exposure. Toxicol Sci (2003) 0.94
Workshop overview: Hepatotoxicity assessment for botanical dietary supplements. Toxicol Sci (2004) 0.93
Neutrophil interaction with the hemostatic system contributes to liver injury in rats cotreated with lipopolysaccharide and ranitidine. J Pharmacol Exp Ther (2007) 0.93
Thrombin and protease-activated receptor-1 agonists promote lipopolysaccharide-induced hepatocellular injury in perfused livers. J Pharmacol Exp Ther (2003) 0.93
A novel CXCR4 antagonist derived from human SDF-1beta enhances angiogenesis in ischaemic mice. Cardiovasc Res (2009) 0.93